Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 2, 2004, Pages 111-119

  Chen, Allan Y ^a   Chou, Rachel ^a   Shih, Shyh Jen ^a   Lau, Derick ^a   Gandara, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 METHYLENEDIOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 TERT BUTYLDIMETHYLSILYL 10 HYDROXYCAMPTOTHECIN; AMIFOSTINE; ANTICONVULSIVE AGENT; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; CARBOPLATIN; CISPLATIN; DB 67; DNA TOPOISOMERASE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GLUTAMINE; HYDROXYUREA; IRINOTECAN; RADIOSENSITIZING AGENT; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BRAIN CANCER; BRAIN RADIATION; CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOXICITY; ESOPHAGITIS; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; LEUKOPENIA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PNEUMONIA; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; TISSUE SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 2442537264     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.09.005     Document Type: Review

References (88)

1. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principle and practice of oncology. 6th ed. Philadelphia: J.B. Lippincott; 2001.
2. Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 3rd ed. Philadelphia: J.B. Lippincott; 1998.
3. Cox J, Ang KK, editors. Radiation oncology - rationale, technique, results. 8th ed. Philadelphia: Mosby; 2003.
4. Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia: J.B. Lippincott; 2000.
5. John M, Flam M, Legha S, Phillips T, editors. Chemoradiation: an integrated approach to cancer treatment. 1st ed. Philadelphia: J.B. Lippincott; 1995.
6. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleotides. J. Natl. Cancer Inst. 88:1996;1193-1203
7. Chen A.Y., Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:1994;191-218
8. Li T.K., Liu L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41:2001;53-77
9. Liehr JG, Giovanella BC, Verschraegen CF, editors. The Camptothecins - unfolding their anticancer potential. Ann N Y Acad Sci 2000.
10. Mattern M.R., Hofmann G.A., McCabe F.L., Johnson R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 51:1991;5813-5816
11. Kim J.H., Kim S.H., Kolozsvary A., Khil M.S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;515-518
12. Boothman D.A., Wang M., Schea R.A., Burrows H.L., Strickfaden S., Owens J.K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;939-948
13. Roffler S.R., Chan J., Yeh M.-Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 54:1994;1276-1285
14. Hennequin C., Giocanti N., Balosso J., Favaudon V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54:1994;1720-1728
15. Chen A.Y., Okunieff P., Pommier Y., Mitchell J. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 57:1997;1529-1536
16. Chen A.Y., Choy H., Rothenberg M.L. DNA Topoisomerase I - targeting drugs as radiation sensitizers. Oncology. 13(10 Suppl 5):1999;39-46
17. Gellert M. DNA topoisomerases. Annu. Rev. Biochem. 50:1981;879-910
18. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 3(6):2002;430-440
19. Hsiang Y.-H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878
20. Hsiang Y.-H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726
21. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 84:1987;5565-5569
22. Nitiss J., Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. U.S.A. 85:1988;7501-7505
23. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicolas A.W., Liu L.F., et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 246:1989;1046-1048
24. Potmesil M., Hsiang Y.-H., Liu L.F., Bank B., Grossberg H., Kirshenbaum S., et al. Resistance of human leukemic, Resistance of human leukemic & normal lymphocytes to drug-induced DNA cleavage & low levels of DNA topoisomerase II. Cancer Res. 48:1988;3537-3543
25. Hwang J., Shyy S., Chen A.Y., Juan C.-C., Whang-Peng J. Studies of topo-specific anti-tumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase I polypeptide. Cancer Res. 49:1989;958-962
26. Pantazis P., Early J.A., Kozielski A.J., Mendoza J.T., Hinz H.R., Giovanella B.C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res. 53:1993;1577-1582
27. Pantazis P., Kozielski A.J., Mendoza J.T., Early J.A., Hinz H.R., Giovanella B.C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between of nontumorigenic and tumorigenic cells in vitro. Int. J. Cancer. 53:1993;863-871
28. Hsiang Y.-H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082
29. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese Hamster DC3F cells. Cancer Res. 49:1989;6365-6368
30. Zhang H., D'Arpa P., Liu L.F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells. 2:1990;23-27
31. D'Arpa P., Beardmore C., Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924
32. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8131-8135
33. Chen A.Y., Yu C., Bodley A., Peng L.F., Liu L.F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53:1993;1332-1337
34. Chen A.Y., Yu C., Gatto B., Liu L.F. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by the antitumor anthracycline nogalamycin. Proc. Am. Assoc. Cancer Res. 35:1994;2723
35. Sim S.P., Gatto B., Yu C., Liu A.A., Li T.K., Pilch D.S., et al. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. Biochemistry. 36:1997;13285-13291
36. Pantazis P, Giovanella BC, Rothenberg ML, editors. The camptothecins from discovery to the patient. New York: New York Academy of Sciences; 1996.
37. Yamashita Y., Fujii N., Murakata C., Ashizawa T., Okabe M., Nakano H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 31:1992;12069-12075
38. Yoshinari T., Yamada A., Uemura D., Nomura K., Arakawa H., Kojiri K., et al. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 53:1993;490-494
39. Yoshinari T., Matsumoto M., Arakawa H., Okada H., Noguchi K., Suda H. Novel antitumor indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2, 3-a]pyrrolo[3, 4-c]carbazole-5, 7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 55:1995;1310-1315
40. Yoshinari T., Ohkubo M., Fukasawa K., Egashira S., Hara Y., Matsumoto M., et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 59:1999;4271-4275
41. Bailly C., Riou J.F., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry. 36:1997;3917-3929
42. Bailly C., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M., Waring M.J. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol. 53:1998;77-87
43. Labourier E., Riou J.F., Prudhomme M., Carrasco C., Bailly C., Tazi J. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res. 59:1999;52-55
44. Bailly C., Qu X., Anizon F., Prudhomme M., Riou J.F., Chaires J.B. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol. Pharmacol. 55:1999;377-385
45. Takimoto C.H., Wright J., Arbuck S.G. Clinical applications of the camptothecins. Biochem. Biophys. Acta. 1400(1-3):1998;107-119
46. Clinical status and future directions of Irinotecan. Oncology 1998;12(8 Suppl 6):1-128.
47. Choy H., Macrae R. Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology. 15(7 Suppl 8):2001;22-28
48. Chen A.Y., Yu C., Pomesil M., Wall M.E., Wani M.C., Liu L.F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51:1991;6039-6044
49. Chen AY, Liu LF. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance in human cancers. In: Liu LF, editor. DNA Topoisomerases. Dordrecht: Kluwer Academic Publishers; 1994. p. 245-56.
50. Pollack I.F., Erff M., Bom D., Burke T.G., Strode J.T., Curran D.P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. 59(19):1999;4898-4905
51. Bom D., Curran D.P., Kruszewski S., Zimmer S.G., Thompson Strode J., Kohlhagen G., et al. The novel silatecan 7-tert-butyldimethylsilyl-10- hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 43(21):2000;3970-3980
52. Munro T.R. The relative radiosensitivity of the nucleus and cytoplasm of the Chinese hamster fibroblasts. Radiat. Res. 42:1970;451-470
53. Radford I.R. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int. J. Radiat. Biol. 49:1986;611-620
54. Herscher L.L., Cook J.A., Pacelli R., Pass H.I., Russo A., Mitchell J.B. Principles of chemoradiation: theoretical and practical considerations. Oncology. 13(10 Suppl 5):1999;11-22
55. Chen A.Y., Hsiao M., Li L., Rothenberg M., Burke T.G., Curran D.P. Silatecan DB-67 induces DNA topoisomerase I-mediated radiosensitization in human glioma cells. Proc. Am. Assoc. Cancer Res. 42:2001;4678
56. Chen A.Y., Scruggs P.B., Geng L., Hallahan D.E. p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiosensitization in mammalian cells. Ann. N. Y. Acad. Sci. 922:2000;298-300
57. Tsao Y.P., Russo A., Nyamuswa G., Silber R., Liu L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53(24):1993;5908-5914
58. Elkind M.M., Sutton-Gilbert H., Moses W.B., Alescio T., Swain R.B. Radiation response of mammalian cells in culture: V Temperature dependence of the repair of X-ray damage in surviving cells (aerobic and hypoxic). Radiat. Res. 25:1965;359-376
59. Hare C.B., Elion G.B., Houghton P.J. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 39(3):1997;187-191
60. Coggins C.A., Elion G.B., Houghton P.J., et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41(6):1998;485-490
61. Friedman H.S., Petros W.P., Friedman A.H., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17(5):1999;1516-1525
62. Berben V.M.M., Schellens J.H.M., Swart M., et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J. Clin. Oncol. 17(6):1999;1897-1905
63. Cloughesy T.F., Filka E., Nelson G., Kabbinavar F., Friedman H., Miller L.L., et al. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am. J. Clin. Oncol. 25(2):2002;204-208
64. Fisher B., Won M., Macdonald D., Johnson D.W., Roa W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int. J. Radiat. Oncol. Biol. Phys. 53(4):2002;980-986
65. Pickren J.W., Lopez G., Tsukada Y., et al. Brain metastases. An autopsy study. Cancer Treat. Symp. 2:1983;295-313
66. Hendrickson F. The optimum schedule for palliative radiotherapy for metastatic brain cancer. Int. J. Radiat. Oncol. Biol. Phys. 2:1977;165-168
67. Borgelt B., Gelber R., Kramer S., et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6:1980;1-9
68. Coia L.R. The role of radiation therapy in the treatment of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 23:1991;229-238
69. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, editors. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29.
70. Patchell R.A., Tibbs P.A., Walsh J.W., Dempsey R.J., Maruyama Y., Kryscio R.J., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8):1990;494-500
71. Patchell R.A. The treatment of brain metastases. Cancer Invest. 14(2):1996;169-177
72. Bourhis J., Pignon J.P., Designe M., Luboinski S., Guerin S., Domenge C. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) loco-regional treatment vs. same treatment + chemotherapy (CT) [abstract]. Proc. Am. Soc. Clin. Oncol. 17:1998;386
73. Murphy B.A., Cmelak A., Burkey B., Netterville J., Shyr Y., Douglas S., et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology. 15(7 Suppl 8):2001;47-52
74. Koukourakis M.I., Bizakis J.G., Skoulakis C.E., Kyrmizakis D., Giatromanolaki A., Papadakis C.E., et al. Combined irinotecan. Anticancer Res. 19:1999;2309-2310
75. Humerickhouse R.A., Haraf D., Stenson K., Brockstein B., Gordon G., Marrero T., et al. Phase I study of irinotecan (CPT-11), 5-FU, and hydroxyurea with radiation in recurrent or advanced head and neck cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 19:2000;418a
76. Bourhis J., De Crevoisier R., Abdulkarim B., et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(5):2000;1105-1108
77. Schonekas K.G., Wagner W., Prott F.J., et al. Amifostine: A radioprotector in locally advanced head and neck tumors. Strahlenther Onkol. 175(Suppl 4):1999;27-29
78. Huang E.-Y., Leung S.W., Wang C.-J., et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 46(3):2000;535-539
79. Bump, Malaker, editors. Radioprotectors: chemical, biological and clinical perspectives. Boca Raton (FL): CRC Press; 1998.
80. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17:1999;658-667
81. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:2002;85-91
82. Fukuoka M., Niitani H., Suzuki A., et al. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10:1992;16-20
83. Negoro S., Masuda N., Takada Y., et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer. 88:2003;335-341
84. Graham M.V., Jahanzeb M., Dresler C.M., et al. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;1215-1220
85. Takeda K., Negoro S., Okishio K., et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br. J. Cancer. 79:1999;1462-1467
86. Choy H., Chakravarthy A., Devore R.F., et al. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology. 14:2000;43-46
87. Yokoyama A., Kurita Y., Saijo N., et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br. J. Cancer. 78:1998;257-262
88. Yamada M., Kudoh S., Fukuda H., et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small-cell lung cancer. Br. J. Cancer. 87:2002;258-263